Emergent BioSolutions (EBS) EBIT Margin (2011 - 2026)

Emergent BioSolutions' EBIT Margin history runs 16 years deep, the most recent figure standing at 6.73% for Q1 2026.

• In Q1 2026, EBIT Margin fell 1573.0% year-over-year to 6.73%; the TTM figure through Mar 2026 stood at 8.97% (up 2193.0% YoY), while the FY2025 annual figure was 13.47%, up 2389.0% from the prior year.
• EBIT Margin was 6.73% for Q1 2026 at Emergent BioSolutions, up from 18.76% in the prior quarter.
• In the past five years, EBIT Margin ranged from a high of 33.1% in Q3 2025 to a low of 407.0% in Q2 2024.
• Historically, EBIT Margin has averaged 39.92% across 5 years, with a median of 15.84% in 2023.
• The sharpest annual moves came in 2024 and 2025: EBIT Margin tumbled 32032 bps in 2024, then soared 40814 bps in 2025.
• A 5-year view of EBIT Margin shows it stood at 16.75% in 2022, then climbed by 5 bps to 15.84% in 2023, then surged by 69 bps to 4.88% in 2024, then plunged by 285 bps to 18.76% in 2025, then surged by 136 bps to 6.73% in 2026.
• The last three EBIT Margin figures came in at 6.73% (Q1 2026), 18.76% (Q4 2025), and 33.1% (Q3 2025), per Business Quant data.